Hypotensive mechanisms of amifostine

Journal of Clinical Pharmacology

Volumn 36, Issue 4, 1996, Pages 365-373

  Ryan, Sean V ^a   Carrithers, Stephen L ^a   Parkinson, Scott J ^a   Skurk, Carsten ^b   Nuss, Charles ^b   Pooler, Patricia M ^b   Owen, Charles S ^b   Lefer, Allan M ^b   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 2 [2 (4 HYDROXYPHENYL)ETHYLAMINOMETHYL]TETRALONE I 125; ACETYLCHOLINE; ADENYLATE CYCLASE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIFOSTINE; ATRIAL NATRIURETIC FACTOR; CALCIUM; CYCLIC AMP; CYCLIC GMP; EPHEDRINE; FORSKOLIN; GUANYLATE CYCLASE; INDOMETACIN; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; NORADRENALIN; PHENTOLAMINE; PHENYLEPHRINE; PRAZOSIN; PROSTAGLANDIN; SODIUM NITRITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; B LYMPHOCYTE; BRAIN MEMBRANE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DOSE RESPONSE; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; RAT; RECEPTOR BINDING; SMOOTH MUSCLE RELAXATION; VASCULAR RING; VASCULAR SMOOTH MUSCLE;

EID: 0030002421     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04214.x     Document Type: Article

References (25)

1. Glover DJ, Glick JH, Weiler C, Fox K, Turrisi A, Kligermann MM: Phase I/II tirais of WR-2721 and cisplatin. Int J Radiat Oncol Biol Phys 1986;12:1509-1512.
2. Glover DJ, Glick JH, Weiler C, Hurwitz S, Kligermann MM: WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986;4:584-588.
3. Glover DJ, Glick JH, Weiler C, Fox K, Guerry D: WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987;5:574-578.
4. Schein PS: WR-2721: a chemotherapy and radiation-protective agent. Cancer Invest 1990;8:265-266.
5. Turrisi AT, Glover DJ, Hurwitz S, Glick J, Norfleet AL, Weiler C, et al: Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)-ethylphosphorothioic acid]. Cancer Treat Rep 1986;70:1389-1393.
6. Yuhas JM, Spellmann JM, Culo F: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980;3:211-216.
7. US Biosciences: Confidential Investigators Brochure: Ethyol (Amifostine; WR-2721). West Conshohocken, PA: US Biosciences, 1991.
8. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward GF: Alkaline phosphatase promotes radioprotective effects of the transported form of the drug. Cancer Res 1988;48:3641-3647.
9. Caldwell RW, Heiffer MH: Acute cardiovascular and autonomic effects of WR-2721: a radioprotective compound. Radiat Res 1975;62:62-69.
10. Herman EH, Heifer MH, Demaree GE, Fick JA: Alpha-adrenergic antagonism by a series of aliphatic sulfur-containing compounds. Arch Int Pharmacodyn Ther 1971;193:102-110.
11. Bennett B, Molina C, Waldman SA, Murad F: Cyclic nucleotides and protein phosphorylation in vascular smooth muscle relaxation. In, Sperelakis N (ed.): Physiology and Pathology of the Heart. Boston: Kluwer Academic Publishers, 1989;825-846.
12. 125I]BE 2254, a new high affinity radioligand for α-adrenoceptors. Eur J Pharmacol 1981;73:221-224.
13. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450.
14. Owen CS: Quantitation of lymphocyte intracellular free calcium signals using indo-1. Cell Calcium 1988;9:141-147.
15. Owen CS: Phorbol ester (12-O-tetradecanoylphorbol 13-acetate) partially inhibits rapid intracellular free calcium transients triggered by anti-immunoglobulin in murine lymphocytes. J Biol Chem 1988;263:2732-2737.
16. Gazzano H, Wu I, Waldman SA: Adenine nucleotide regulation of particulate guanylate cyclase from rat lung. Biochim Biophys Acta 1991;1077:99-106.
17. Fiscus RR, Rapoport RM, Waldman SA, Murad F: Atriopeptin II elevates cyclic GMP, activates cyclic GMP-dependent protein kinase and causes relaxation in rat thoracic aorta. Biochim Biophys Acta 1985;846:179-184.
18. Harper JF, Brooker G: Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res 1975;1: 207-218.
19. Johnson RA, Salomon Y: Assay of adenylyl cyclase catalytic activity. Methods Enzymol 1991;16:3-21.
20. 1-adrenergic receptors and stimulation of [3H]inositol metabolism in rat brain: regional distribution and parallel inactivation. Brain Res 1985;341:7-15.
21. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R: Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 1979;122:549-554.
22. 2+ in anti-Ig-stimulated B lymphocytes is dependent on activation of phosphoinositide hydrolysis. J Immunol 1988;140:3150-3157.
23. Cockcroft JR, Toy JL, Ritter JM: Lack of the effect of ethyol (WR-2721) on forearm bloodflow in healthy volunteers. Eur J Clin Pharmacol 1993;44:103-104.
24. Cook NS: The pharmacology of potassium channels and their therapeutic potential. Trends Pharmacol Sci 1988;9:21-28.
25. Clarencon D, Golonnier M, Yestylier G, Fatome M: Influence of the radioprotective agent WR 2721 on the striatal acetylcholinesterase activity in the rat. Brain Res 1993;608:155-158.